Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal

Vemurafenib for the treatment of unresectable locally advanced or metastatic, BRAF\textsuperscript{V600} mutation positive malignant melanoma

Matrix of consultees and commentators

<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturers/sponsors</td>
<td>General</td>
</tr>
<tr>
<td>● Roche Products (vemurafenib)</td>
<td>● Board of Community Health Councils in Wales</td>
</tr>
<tr>
<td>Patient/carer groups</td>
<td>● British National Formulary</td>
</tr>
<tr>
<td>● Action for Children (formerly known as) NCH – The Children’s Charity</td>
<td>● Care Quality Commission</td>
</tr>
<tr>
<td>● Action for Sick Children</td>
<td>● Commissioning Support Appraisals Service</td>
</tr>
<tr>
<td>● Aflya Trust</td>
<td>● Department of Health, Social Services</td>
</tr>
<tr>
<td>● Association for Children with Life Threatening or Terminal Conditions</td>
<td>and Public Safety for Northern Ireland</td>
</tr>
<tr>
<td>● Black Health Agency</td>
<td>● Health Improvement Scotland</td>
</tr>
<tr>
<td>● Cancer 52</td>
<td>● Medicines and Healthcare products</td>
</tr>
<tr>
<td>● Cancer Black Care</td>
<td>Regulatory Agency</td>
</tr>
<tr>
<td>● Cancer Equality</td>
<td>● National Association of Primary Care</td>
</tr>
<tr>
<td>● CLIC Sargent</td>
<td>● NHS Alliance</td>
</tr>
<tr>
<td>● Counsel and Care</td>
<td>● NHS Commercial Medicines Unit</td>
</tr>
<tr>
<td>● Equalities National Council</td>
<td>● NHS Confederation</td>
</tr>
<tr>
<td>● Factor 50</td>
<td>● Public Health Wales NHS Trust</td>
</tr>
<tr>
<td>● Helen Rollason Heal Cancer Charity</td>
<td>● Scottish Medicines Consortium</td>
</tr>
<tr>
<td>● Help Adolescents with Cancer</td>
<td></td>
</tr>
<tr>
<td>● Macmillan Cancer Support</td>
<td>Comparator manufacturer(s)</td>
</tr>
<tr>
<td>● Maggie’s Centres</td>
<td>● Bayer (dacarbazine)</td>
</tr>
<tr>
<td>● Marie Curie Cancer Care</td>
<td>● Bristol-Myers Squibb (ipilimumab)</td>
</tr>
<tr>
<td>● Muslim Council of Britain</td>
<td>● Hospira UK (dacarbazine)</td>
</tr>
<tr>
<td>● Muslim Health Network</td>
<td>● Medac UK (dacarbazine)</td>
</tr>
<tr>
<td>● National Alliance of Childhood Cancer Parent Organisations</td>
<td>● PLIVA Pharma (dacarbazine)</td>
</tr>
<tr>
<td>● National Children’s Bureau</td>
<td>Relevant research groups</td>
</tr>
<tr>
<td>● Rarer Cancers Foundation</td>
<td>● British Society for Dermatological Surgery</td>
</tr>
<tr>
<td>● Skin - Karen Clifford Skin Cancer Charity</td>
<td>● Cochrane Skin Group</td>
</tr>
<tr>
<td>● Skin Care Campaign</td>
<td>● Institute of Cancer Research</td>
</tr>
<tr>
<td>● South Asian Health Foundation</td>
<td>● MRC Clinical Trials Unit</td>
</tr>
<tr>
<td>● Specialised Healthcare Alliance</td>
<td>● Melanoma Study group</td>
</tr>
<tr>
<td>● Teenage Cancer Trust</td>
<td>● Myfanwy Townsend Melanoma Research Fund</td>
</tr>
</tbody>
</table>

National Institute for Health and Clinical Excellence
Provisional matrix for the proposed appraisal of vemurafenib for the treatment of unresectable locally advanced or metastatic, BRAF\textsuperscript{V600} mutation positive malignant melanoma

Issue date: November 2011
## Consultees

- Tenovus
- Well Child

### Professional groups

- Association of Cancer Physicians
- British Association for Services to the Elderly
- British Association for Surgical Oncology (BASO)
- British Association of Dermatologists
- British Association of Skin Cancer Specialist Nurses
- British Dermatological Nursing Group
- British Geriatrics Society
- British Institute for Radiologists
- British Psychosocial Oncology Society
- British Skin Foundation
- Cancer Networks Pharmacists Forum
- Cancer Research UK
- National Pharmacy Association
- Primary Care Dermatology Society
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

### Others

- Department of Health
- NHS Birmingham East and North
- NHS East Lancashire
- Welsh Assembly Government

## Commentators (no right to submit or appeal)

- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
- Research Institute of the Care of Older People
- Skin Cancer Research Fund
- Skin Research Centre
- Skin Treatment & Research Trust

### Evidence Review Group

- Liverpool Reviews & Implementation Group, University of Liverpool
- National Institute for Health Research Health Technology Assessment Programme

### Associated Guideline Groups

- National Collaborating Centre for Cancer

### Associated Public Health Groups

- tbc
NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS
Appendix C

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

1 Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

National Institute for Health and Clinical Excellence
Provisional matrix for the proposed appraisal of vemurafenib for the treatment of unresectable locally advanced or metastatic, BRAFV600 mutation positive malignant melanoma

Issue date: November 2011